Considering the anti-inflammatory and antifibrotic effects of PCSK9 inhibition, blockage of PCSK9 may have multiple beneficial effects in patients with liver cirrhosis [44,57]. The gene discussed is PCSK9; the disease is cirrhosis of liver.